Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Lung Cancer: early-phase trial registry
146 of 430 indexed Lung Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #12 of 28,963 conditions by registered trial count.
430 US clinical trials · 146 currently recruiting · #12 of 28,963 conditions by registered trial count
Lung Cancer: 430 US clinical trials tracked, 146 recruiting.
Lung Cancer is the subject of 430 registered US clinical trials on ClinicalTrials.gov, 146 of them currently open to new participants. 23 are in Phase 3-4 (later-stage) and 181 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 36 of these trials.
Open enrollment, early-phase tilt
Lung Cancer has 430 registered US clinical trials, 146 of them open to new participants right now, about 34% of the total.
- 146
- recruiting participants now
- 34%
- of trials open to enrollment
- 23
- in Phase 3-4 (later-stage)
- 36
- top sponsor: Memorial Sloan Kettering Cancer Center
Corpus placement: #12 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.
Key findings
What ClinicalTrials.gov does not surface for Lung Cancer on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.
-
Lung Cancer is recruiting below its size-band peers.
146 of 430 indexed trials (34%) are open to enrollment, against a 37.2% average across 135 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Lung Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 36 of 430 trials (8.4%). 179 distinct sponsors appear on at least one study for this condition label.
-
Typical Lung Cancer enrolment sits around 89 participants.
Median target enrolment is 89 among the 410 trials that report a genuine target (sentinel values excluded). 212 of those (51.7%) plan for fewer than 100 participants.
-
Lung Cancer research is mostly interventional.
321 interventional and 109 observational studies make up this index (74.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
430 total, page 2 of 9
A Patient and Provider Intervention to Address Health Disparities in Lung Cancer Screening
Georgetown University
NCT04675476
Adaptation and Pilot Testing of a Lung Cancer Screening Decision Aid for Patients From a Safety-Net Healthcare System
M.D. Anderson Cancer Center
NCT07382557
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
Taiho Oncology
NCT07128199
Improving Care for Rural Patients With Solid Tumors
University of Colorado, Denver
NCT04916990
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals
NCT04585750
Couple-Based Meditation for Metastatic Lung Cancer Patients and Their Partners
M.D. Anderson Cancer Center
NCT02596490
Precision Lung Cancer Survivorship Care Intervention
Jerod L Stapleton, PhD
NCT05857995
Assessment of a Radiomics-based Computer-Aided Diagnosis Tool for Pulmonary nodulES
Abramson Cancer Center at Penn Medicine
NCT05968898
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
SystImmune
NCT06293898
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
Fox Chase Cancer Center
NCT05800587
Implementation and Effectiveness of the BJC-Pink and Pearl Project on Lung Cancer Screening
Washington University School of Medicine
NCT06898333
Study of Novel Treatment Combinations in Patients With Lung Cancer
Gilead Sciences
NCT05633667
Mobile Application to Improve Health-Related Outcomes in Patients With Advanced Lung Cancer
Massachusetts General Hospital
NCT06427954
EBUS-TBNA vs Transbronchial Mediastinal Cryobiopsy for Adequacy of Next Generation Sequencing
Vanderbilt-Ingram Cancer Center
NCT06105801
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
VM Oncology
NCT03556228
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
A2 Biotherapeutics
NCT06682793
The Lung PCA: A Multi-Dimensional Atlas of Pulmonary Premalignancy
University of Colorado, Denver
NCT03881098
Pathways, a Hope Intervention to Support Personal Goal Pursuit, Mental Health, and Quality of Life During Advanced Lung Cancer Treatment
Laurie McLouth
NCT06047301
Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer
Canadian Cancer Trials Group
NCT04093167
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
Circle Pharma
NCT06577987
Confocal Laser Endomicroscopy VERification
Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)
NCT06079970
Metabolic Biomarkers in Thoracic Cancers
University of Texas Southwestern Medical Center
NCT02095808
Image Guided VATS vs. VATS Resection
Brigham and Women's Hospital
NCT03623958
Goals of Care Discussion for Patients With Advanced Lung and Gastrointestinal Cancer in the Emergency Department of a Comprehensive Cancer Center
M.D. Anderson Cancer Center
NCT06420206
Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers
Stanford University
NCT00568490
Prospective Study to Evaluate High Flow Nasal Cannula With Monitored Anesthesia Care During EBUS Bronchoscopy
The Cooper Health System
NCT05203328
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Tango Therapeutics
NCT06810544
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Tango Therapeutics
NCT06922591
Healthy Homes Study
Dartmouth-Hitchcock Medical Center
NCT05833334
Piloting a Virtual Navigation (VN) System for Bronchoscopic Lung Nodule Sampling
Penn State University
NCT05599321
Maximizing Lymph Node Dissection on Fresh and Fixed Lung Cancer Resection Specimens
Brigham and Women's Hospital
NCT06252129
ATATcH Alternating Treatment Plans for Advanced Cancer
Rutgers, The State University of New Jersey
NCT05358548
Increasing Equity in Lung Cancer Screening
Indiana University
NCT06360822
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
Daiichi Sankyo
NCT06644768
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RasCal Therapeutics
NCT04678648
A Study of Mental Health Care in People With Cancer
Memorial Sloan Kettering Cancer Center
NCT06037954
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
Tango Therapeutics
NCT05887492
DREAM: Double Lung Transplant REgistry Aimed for Lung-limited Malignancies
Northwestern University
NCT05671887
Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy
Bo Lu
NCT06410300
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
AstraZeneca
NCT06973161
COPD Care Pathway Among Patients With Cancer
Wake Forest University Health Sciences
NCT05984680
Exercise as Maintenance Therapy in Advanced Lung Cancer
Indiana University
NCT06513663
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Nammi Therapeutics
NCT06582017
Incentive Spirometry to Improve Outcomes in Lung Cancer Patients Undergoing Concurrent Chemotherapy and Radiation Therapy
The Cooper Health System
NCT06688422
Study Comparing Two Different Schedules of Radiation for Early-stage Lung Cancer
University of Rochester
NCT03706027
Community Support Program for Lung Cancer Screening Volume II
Abramson Cancer Center at Penn Medicine
NCT06628167
The Florida ASCENT Study
University of Florida
NCT07042243
Leveraging the Emergency Department (LEAD) Study
Hackensack Meridian Health
NCT06605534
4D-MRI for Precision Medicine
University of Virginia
NCT04657042
Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients
Massachusetts General Hospital
NCT03535545
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 85 |
| Phase 2 | 96 |
| Phase 3 | 22 |
| Phase 4 | 1 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
What is open for Lung Cancer right now
146 recruiting of 430 indexed (34% open).
Phase mix: 23 late (III/IV) vs 181 early (I/II) (early-phase heavy).
Top sponsor: Memorial Sloan Kettering Cancer Center (36 trials), 9 others listed. 50 shown below, recruiting first. #12 of 28,963 conditions by registered trial count.
How open-enrollment share is computed
Open share is recruiting_count divided by trial_count for this condition label in the public registry export. Status can change between pulls; treat the figure as a snapshot of research attention, not treatment availability.
Frequently Asked Questions
How many clinical trials are there for Lung Cancer?
PlainTrial tracks 430 US clinical trials for Lung Cancer, of which 146 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Lung Cancer?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.